Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 8,144 matching trials from the live ClinicalTrials.gov search.
Filters: Phoenix, Arizona Clear all
Completed Phase 2 Interventional Results available

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

NCT01149421
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Phoenix, Arizona • Anaheim, California • Greenbrae, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 19, 2026, 2:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

NCT03915184
View directory record Official record
Conditions
Multiple Myeloma
Interventions
zevor-cel
Biological
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 79 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
12
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 2 Interventional

NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction

NCT01495364
View directory record Official record
Conditions
ST Segment Elevation Myocardial Infarction
Interventions
NBS10, placebo
Biological · Other
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
58
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

NCT01335464
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
placebo, BIBF 1120
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
24
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 19, 2026, 2:22 AM EDT
Active, not recruiting Phase 3 Interventional

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

NCT05943106
View directory record Official record
Conditions
Non-Muscle- Invasive Bladder Cancer
Interventions
Durvalumab, BCG
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 2 Interventional

A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers

NCT01070433
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
MEBO Wound Ointment (MEBO), Standard of Care
Drug · Other
Lead sponsor
Skingenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Castro Valley, California • Encinitas, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 19, 2026, 2:22 AM EDT
Terminated Phase 2 Interventional Results available

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

NCT04698187
View directory record Official record
Conditions
Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
Interventions
CMP-001, Nivolumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 19, 2026, 2:22 AM EDT
Not yet recruiting Phase 1 Interventional

Safety Study of XT-150 in Participants With ALS

NCT06704347
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
XT-150
Biological
Lead sponsor
Xalud Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
4
States / cities
Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents

NCT06036134
View directory record Official record
Conditions
Vaccine-Preventable Diseases, COVID-19 Pandemic, Health-Related Behavior, Health Knowledge, Attitudes, Practice, Narration
Interventions
Baseline surveys, Digital Storytelling Intervention, Information Control Intervention
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 3 Interventional

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

NCT00393952
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/Formoterol fumarate 250/10, Placebo, Fluticasone propionate/Formoterol fumarate 100/10, Fluticasone propionate 250, Formoterol fumarate 10
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
62
States / cities
Pell City, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 19, 2026, 2:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

NCT04577963
View directory record Official record
Conditions
Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer
Interventions
Fruquintinib, Tislelizumab
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 19, 2026, 2:22 AM EDT
Recruiting Phase 3 Interventional

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07564414
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Cagrisema, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
99
States / cities
Birmingham, Alabama • Pelham, Alabama • Gilbert, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

NCT04126213
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT 60 µg, RSV MAT 120 µg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 4 Interventional Results available

A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population

NCT02618382
View directory record Official record
Conditions
Subdural Hematoma
Interventions
Tranexamic Acid
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders

NCT00547196
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
filgrastim, Busulfan, Cyclophosphamide, Cyclosporine, Fludarabine phosphate, Melphalan, Mycophenolate Mofetil, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation, Fractionated total body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
0 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
2
States / cities
Phoenix, Arizona • Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

NCT03104374
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
72
States / cities
Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

NCT01746420
View directory record Official record
Conditions
Lateral Epicondylitis
Interventions
rhPDGF-BB Injection, Placebo
Drug
Lead sponsor
BioMimetic Therapeutics
Industry
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 19, 2026, 2:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

NCT04455750
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
414
States / cities
Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 298 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01313624
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 19, 2026, 2:22 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

NCT01737879
View directory record Official record
Conditions
Anemia
Interventions
Peginesatide, Epoetin alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Tempe, Arizona • Azusa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

NCT03633396
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Imsidolimab, Placebo
Biological · Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 19, 2026, 2:22 AM EDT
Completed No phase listed Observational

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT02815891
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
2 Years and older
Enrollment
7,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
65
States / cities
Phoenix, Arizona • Palo Alto, California • Pasadena, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive

NCT00362479
View directory record Official record
Conditions
Contraception
Interventions
DR-1021
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,347 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
85
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 19, 2026, 2:22 AM EDT